BlackThorn Therapeutics has been selected as one of the “Fierce 15” winners for 2017. With this designation, BlackThorn is considered one of the “up-and-coming privately-held biotech companies expected to make big waves in the industry.” The annual Fierce 15 list celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.

This year, FierceBiotech evaluated a record number of nominations submitted by readers and editors of the publication, and selected the winners based on a variety of factors, including strength of technology, partnerships, venture backers and a competitive market position. FierceBiotech’s full list of winners can be found here.

With a strong financial position, novel approach to CNS drug development, and robust pipeline of first- and best-in-class treatments, the company is well positioned to achieve its goal of becoming a leading neurobehavioral health company – and, importantly, to move toward a future where patients with neurobehavioral disorders are effectively treated.